Nathan Tumey
Assistant Graduate Director; Vice Chair and Associate Professor, Pharmaceutical Sciences
School of Pharmacy and Pharmaceutical Sciences
Background
L. Nathan Tumey joined Binghamton University in 2017, following 15 years of medicinal chemistry experience in the pharmaceutical and biotechnology industry. His research focuses on the design of antibody-drug-conjugates (ADCs) for the treatment of cancer, auto-immune disorders and rare diseases. Specific research projects include immune-stimulating antibody conjugates, glucocorticoid-antibody conjugates, legumain-cleavable linkers, and site-specific conjugation technology. Tumey is a leading expert in ADC technology, particularly as it applies to bioconjugation, linker design and immune-modulating payloads. He is a frequent consultant at various biotechnology and pharmaceutical companies and serves on the scientific advisory board of multiple ADC-related organizations.
Tumey received his PhD in chemistry from Duke University in 2001, under the supervision of Michael Pirrung. During his years in the pharmaceutical industry, Tumey was a key leader in multiple drug-discovery programs including the development of 5HT2c agonists for obesity, PKC-theta inhibitors for asthma, IRAK4 inhibitors for rheumatoid arthritis and antibody-drug-conjugates (ADCs) for the treatment of cancer.
Education
- BS, King University
- PhD, Duke University
Research Interests
- Medicinal chemistry
- Targeted drug delivery
- Antibody-drug conjugates
- Auto-immune disease / inflammation
